Bayer and J&J wrap positive PhIII cardio study for Xarelto


February 8, 2017

Bayer and its part­ners at J&J, back in the fall of 2012, started a mas­sive study to see if the drug Xarelto (ri­varox­a­ban) could help pre­vent major car­dio­vas­cu­lar events like my­ocar­dial in­farc­tion, stroke, and death in high risk pa­tients with coro­nary artery dis­ease or pe­riph­eral artery dis­ease.

Very recently, a lit­tle more than 4 years and 27,000-plus pa­tients later, in­ves­ti­ga­tors say that they hit the pri­mary end­point well ahead of sched­ule. Now they’re end­ing the trial early and launch­ing an ex­ten­sion study where they will con­tinue to dose pa­tients.

Pa­tients randomly re­ceived ei­ther ri­varox­a­ban 2.5 mg twice daily with as­pirin 100 mg once daily, ri­varox­a­ban 5 mg twice daily alone, or as­pirin 100 mg once daily alone.

There’s no data yet, but the com­pany says that the huge study de­liv­ered “over­whelm­ing” ev­i­dence of the ef­fi­cacy of the drug.

“De­spite es­tab­lished and ef­fec­tive treat­ments, an unmet med­ical need in this pa­tient pop­u­la­tion still ex­ists with rates of CAD and PAD ris­ing glob­ally. Bayer is com­mit­ted to an on­go­ing clin­i­cal de­vel­op­ment pro­gramme that ad­dresses such unmet med­ical needs. We are ex­cited about these re­sults and look for­ward to mak­ing ri­varox­a­ban avail­able to pa­tients with CAD and PAD to re­duce their risk of major ad­verse car­diac events,” said Dr. Joerg Moeller, a mem­ber of the ex­ec­u­tive com­mit­tee of Bayer AG’s Phar­ma­ceu­ti­cal Di­vi­sion and Head of De­vel­op­ment.


Bayer and J&J wrap positive PhIII cardio study for Xarelto last edit: 2017-02-13T16:36:25+00:00 da Luca
  • Janine Müller
    Posted 18 February 2017 11:59 0Likes

    And what a success: The COMPASS-study has already been prematurely terminated as the criteria for clinical superiority are met. The participants of the study maintain receiving Rivaroxaban in an open-label extension study now.

  • Trackback: Top Pharma News | February – March 2017 – IgeaHub

Leave a Reply

*The views and opinions expressed on IgeaHub belong to the authors only. They do not represent the views or opinions of any company or organization.

Follow Us

Join us

All rights reserved. Terms of use and Privacy Policy

Design by PT Webmaster

%d bloggers like this:
Skip to toolbar